XTRA:AFXMedical Equipment
A Look At Carl Zeiss Meditec (XTRA:AFX) Valuation After Its Fiscal 2025/26 Guidance Revision
Why Carl Zeiss Meditec is back on investors’ radars
Carl Zeiss Meditec (XTRA:AFX) recently warned that its fiscal 2025/26 revenue and EBITA margin targets are unlikely to be met, putting its earnings outlook under formal review and drawing fresh attention to the stock.
See our latest analysis for Carl Zeiss Meditec.
The guidance revision appears to have reset expectations quickly, with a 1 day share price return of 3.75% decline and a 7 day share price return of 21.88% decline at €27.70. The...